Teva Pharmaceutical Industries Future Growth
Future criteria checks 4/6
Teva Pharmaceutical Industries is forecast to grow earnings and revenue by 50.7% and 2.5% per annum respectively. EPS is expected to grow by 42.7% per annum. Return on equity is forecast to be 29.2% in 3 years.
Key information
50.7%
Earnings growth rate
42.7%
EPS growth rate
| Pharmaceuticals earnings growth | 23.6% |
| Revenue growth rate | 2.5% |
| Future return on equity | 29.2% |
| Analyst coverage | Good |
| Last updated | 27 Aug 2024 |
Recent future growth updates
Recent updates
Teva's Transformation: From Generics Leader To Branded Drug Innovator
Aug 14Teva Pharmaceutical Industries Limited (NYSE:TEVA) Second-Quarter Results: Here's What Analysts Are Forecasting For This Year
Aug 02
Teva's Q2 Outlook: Key Developments In Biosimilars And Pipeline Drugs
Jul 26Is Teva Pharmaceutical Industries (NYSE:TEVA) A Risky Investment?
Jul 12Teva Pharmaceutical: Buy This Bargain Before It's Gone
Jun 07Teva Pharmaceutical Industries Limited (NYSE:TEVA) Stock Catapults 27% Though Its Price And Business Still Lag The Industry
May 14Teva: Sustained Revenue Growth Amid Financial Strain (Rating Downgrade)
May 09Teva Pharmaceutical Industries (NYSE:TEVA) Has A Somewhat Strained Balance Sheet
Mar 26Teva Pharmaceutical Industries: Potential Outweighs Concerns
Mar 25Teva And Alvotech: Simlandi Approval Opens New Generic Market Opportunities
Feb 26A Review Of Teva's Prospects
Feb 15Teva Pharmaceutical Industries Limited's (NYSE:TEVA) Business And Shares Still Trailing The Industry
Jan 07These 4 Measures Indicate That Teva Pharmaceutical Industries (NYSE:TEVA) Is Using Debt In A Risky Way
Dec 11Teva: 4 Key Drivers For A 2024 Revival (Upgraded Rating)
Dec 08Teva: Deeply Undervalued FCF Machine
Nov 20Teva: Focus On Innovation And Growth Means The Times They Are A Changing
Sep 14Teva Pharmaceutical Industries (NYSE:TEVA) Has No Shortage Of Debt
Sep 09The Mighty Teva Pharmaceutical: Unveiling A Bullish Scenario You Must Consider
Aug 26Teva Q2 Earnings: Austedo And Anda Growth Impress, But Challenges Remain
Aug 02Teva Pharmaceutical: Lacking Capabilities For Strategic Investments
Jul 20Teva Pharmaceutical: New Growth Plan Could Restore Investor Confidence
Jun 15Here's Why Teva Pharmaceutical Industries (NYSE:TEVA) Is Weighed Down By Its Debt Load
Jun 06Is Teva Pharmaceutical Industries (NYSE:TEVA) A Risky Investment?
Feb 20What To Expect From Teva Pharmaceutical In 2023 With A New CEO
Feb 15Can Teva Pharmaceutical's Q4 results bring positive surprise?
Feb 07Teva Pharmaceutical: Stuck In A Cycle Of Hope And Disappointment
Jan 19Tamiflu supplies released from national stockpile as nationwide shortage persists
Jan 12Teva Pharmaceutical: 2023 Could Finally Be The Stock's Breakout Year
Dec 28Federal appeals court temporarily blocks generics of Vanda's Hetlioz by Teva, Apotex
Dec 16Boston jury orders Lilly to pay $176.5M to Teva in migraine drug patent suit
Nov 10Teva Pharmaceutical to pay New York $523M as part of opioid settlement
Nov 03Teva data indicates long-term benefit of Austedo for chorea associated with Huntington's
Oct 18Novartis division Sandoz reports supply issue of generic ADHD drug Adderall - Bloomberg
Oct 06Teva Pharmaceutical: Slow And Steady Road To A Higher Share Price
Sep 28Teva Pharmaceutical: Past Behind And A Promising 2023
Sep 16Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | 17,334 | 1,740 | 3,412 | 2,161 | 8 |
| 12/31/2025 | 16,814 | 1,503 | 2,840 | 2,280 | 9 |
| 12/31/2024 | 16,213 | -489 | 2,457 | 299 | 8 |
| 6/30/2024 | 16,290 | -453 | 679 | 1,168 | N/A |
| 3/31/2024 | 16,004 | -478 | 878 | 1,389 | N/A |
| 12/31/2023 | 15,846 | -559 | 842 | 1,368 | N/A |
| 9/30/2023 | 15,273 | -2,325 | 608 | 1,157 | N/A |
| 6/30/2023 | 15,017 | -2,350 | 1,173 | 1,695 | N/A |
| 3/31/2023 | 14,925 | -1,711 | 964 | 1,494 | N/A |
| 12/31/2022 | 14,925 | -2,446 | 1,042 | 1,590 | N/A |
| 9/30/2022 | 15,141 | -1,291 | 514 | 1,073 | N/A |
| 6/30/2022 | 15,433 | -1,054 | 476 | 1,059 | N/A |
| 3/31/2022 | 15,557 | -615 | 585 | 1,154 | N/A |
| 12/31/2021 | 15,878 | 417 | 236 | 798 | N/A |
| 9/30/2021 | 16,231 | 726 | 88 | 673 | N/A |
| 6/30/2021 | 16,324 | -3,915 | -131 | 451 | N/A |
| 3/31/2021 | 16,284 | -3,982 | -94 | 506 | N/A |
| 12/31/2020 | 16,659 | -3,990 | 638 | 1,216 | N/A |
| 9/30/2020 | 16,673 | -4,031 | 902 | 1,423 | N/A |
| 6/30/2020 | 16,788 | 4 | 894 | 1,441 | N/A |
| 3/31/2020 | 17,095 | -825 | 413 | 941 | N/A |
| 12/31/2019 | 16,887 | -999 | 223 | 748 | N/A |
| 9/30/2019 | 16,396 | -4,048 | -42 | 577 | N/A |
| 6/30/2019 | 16,831 | -4,007 | 84 | 673 | N/A |
| 3/31/2019 | 17,355 | -3,559 | 449 | 1,062 | N/A |
| 12/31/2018 | 18,271 | -2,399 | 1,795 | 2,446 | N/A |
| 9/30/2018 | 19,693 | -11,059 | 2,233 | 2,938 | N/A |
| 6/30/2018 | 20,781 | -10,256 | 2,534 | 3,312 | N/A |
| 3/31/2018 | 21,800 | -16,050 | N/A | 3,585 | N/A |
| 12/31/2017 | 21,853 | -16,525 | N/A | 2,225 | N/A |
| 9/30/2017 | 23,479 | -5,963 | N/A | 2,791 | N/A |
| 6/30/2017 | 23,425 | -6,145 | N/A | 3,457 | N/A |
| 3/31/2017 | 22,743 | 78 | N/A | 3,985 | N/A |
| 12/31/2016 | 21,903 | 68 | N/A | 3,890 | N/A |
| 9/30/2016 | 20,292 | 1,591 | N/A | 5,415 | N/A |
| 6/30/2016 | 19,552 | 1,346 | N/A | 5,047 | N/A |
| 3/31/2016 | 19,480 | 1,697 | N/A | 5,564 | N/A |
| 12/31/2015 | 19,652 | 1,573 | N/A | 5,542 | N/A |
| 9/30/2015 | 19,939 | 1,775 | N/A | 5,679 | N/A |
| 6/30/2015 | 20,174 | 2,548 | N/A | 6,010 | N/A |
| 3/31/2015 | 20,253 | 2,757 | N/A | 5,583 | N/A |
| 12/31/2014 | 20,272 | 3,055 | N/A | 5,127 | N/A |
| 9/30/2014 | 20,534 | 2,748 | N/A | 4,191 | N/A |
| 6/30/2014 | 20,535 | 2,583 | N/A | 3,211 | N/A |
| 3/31/2014 | 20,414 | 1,383 | N/A | 3,033 | N/A |
| 12/31/2013 | 20,314 | 1,269 | N/A | 3,237 | N/A |
| 9/30/2013 | 20,133 | 1,209 | N/A | 3,998 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: TEVA is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2.5%).
Earnings vs Market: TEVA is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: TEVA is expected to become profitable in the next 3 years.
Revenue vs Market: TEVA's revenue (2.5% per year) is forecast to grow slower than the US market (8.8% per year).
High Growth Revenue: TEVA's revenue (2.5% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: TEVA's Return on Equity is forecast to be high in 3 years time (29.2%)